Cardiff Oncology (NASDAQ:CRDF – Free Report) had its target price hoisted by HC Wainwright from $12.00 to $14.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Cardiff Oncology’s Q1 2024 earnings at ($0.23) EPS, Q2 2024 earnings at […]
N4 Pharma Plc provides an update on its in vitro siRNA research work, showcasing the versatility of their Nuvec® delivery system for cancer treatments.
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) Director Gary W. Pace acquired 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, December 19th. The shares were bought at an average cost of $1.37 per share, for a total transaction of $41,100.00. Following the transaction, the director now owns 697,761 shares […]
Insider Buying: Cardiff Oncology, Inc. (NASDAQ:CRDF) Director Acquires 30,000 Shares of Stock themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Cardiff Oncology, Inc. (NASDAQ:CRDF – Get Free Report) was the recipient of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 1,450,000 shares, a decrease of 9.4% from the November 15th total of 1,600,000 shares. Based on an average daily trading volume, of 688,500 shares, the short-interest […]